Piper Sandler raised the firm’s price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company’s long-term data update in xerostomia and re-acquisition of bota-vec from Johnson & Johnson (JNJ). With the balance sheet bolstered by a concurrent $100M equity raise extending runway into the second half of 2028, Piper continues to like the setup and remains a buyer with a new $30/share target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- MeiraGTx price target raised to $24 from $16 at RBC Capital
- MeiraGTx Announces Public Equity Offering to Fund Growth
- MeiraGTx announces three-year data from Phase 1 AQUAx study
- MeiraGTx announces acquisition of bota-vec for treatment of XLRP
- MeiraGTx Reacquires Bota-Vec Rights, Advances XLRP Program